Head to Head Review: Acorda Therapeutics (ACOR) vs. Its Rivals
Acorda Therapeutics (NASDAQ: ACOR) is one of 282 public companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Acorda Therapeutics to similar businesses based on the strength of its dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership.
Valuation & Earnings
This table compares Acorda Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Acorda Therapeutics||$519.60 million||-$34.61 million||-14.71|
|Acorda Therapeutics Competitors||$286.20 million||$34.74 million||137.22|
Acorda Therapeutics has higher revenue, but lower earnings than its rivals. Acorda Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Acorda Therapeutics has a beta of 1.68, meaning that its share price is 68% more volatile than the S&P 500. Comparatively, Acorda Therapeutics’ rivals have a beta of 2.05, meaning that their average share price is 105% more volatile than the S&P 500.
Institutional & Insider Ownership
49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 7.9% of Acorda Therapeutics shares are held by insiders. Comparatively, 17.2% of shares of all “Bio Therapeutic Drugs” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
This table compares Acorda Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Acorda Therapeutics Competitors||-5,613.30%||-481.92%||-40.09%|
This is a breakdown of current recommendations and price targets for Acorda Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Acorda Therapeutics Competitors||802||3160||11458||229||2.71|
Acorda Therapeutics currently has a consensus price target of $20.75, suggesting a potential upside of 16.57%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.66%. Given Acorda Therapeutics’ rivals stronger consensus rating and higher possible upside, analysts clearly believe Acorda Therapeutics has less favorable growth aspects than its rivals.
Acorda Therapeutics rivals beat Acorda Therapeutics on 8 of the 12 factors compared.
About Acorda Therapeutics
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson’s disease, migraine and MS. The Company’s product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
Receive News & Ratings for Acorda Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.